Recruiting Psoriasis Studies in Indianapolis
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to evaluate the efficacy of bimekizumab administered subcutaneously (sc) compared to active control (ustekinumab) in children and adolescents aged 6 to \<18 years ...
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis....
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis....
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go...
About Psoriasis Clinical Trials in Indianapolis
Psoriasis is a chronic autoimmune skin condition affecting over 8 million Americans, causing cells to build up rapidly on the surface and forming red, scaly patches that can be itchy and painful. Plaque psoriasis accounts for about 80-90% of cases. While current treatments include topical therapies, phototherapy, and biologics like TNF inhibitors (adalimumab, etanercept) and IL-17/IL-23 inhibitors (secukinumab, guselkumab), clinical trials are testing next-generation oral treatments, TYK2 inhibitors, and combination approaches that may offer longer remission periods with fewer side effects. Patients with moderate-to-severe psoriasis who have not responded adequately to existing therapies are often sought for clinical trial enrollment.
There are currently 4 psoriasis clinical trials recruiting participants in Indianapolis, INDIANA. These studies are seeking a combined 368 participants. Research is being sponsored by UCB Biopharma SRL, Organon and Co, Bristol-Myers Squibb and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Psoriasis Clinical Trials in Indianapolis — FAQ
Are there psoriasis clinical trials in Indianapolis?
Yes, there are 4 psoriasis clinical trials currently recruiting in Indianapolis, INDIANA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Indianapolis?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Indianapolis research site will contact you about next steps.
Are clinical trials in Indianapolis free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Indianapolis studies also compensate for your time and travel.
What psoriasis treatments are being tested?
The 4 active trials in Indianapolis are testing new therapies including novel drugs, biologics, and treatment approaches for psoriasis.
Data updated March 2, 2026 from ClinicalTrials.gov